Unfazed by Brexit, PureTech launches Sonde voice diagnostics firm

Life sciences incubator PureTech Health (LON:PRTC), unfazed by the worldwide impact of the U.K.’s vote to leave the European Union, announced its latest venture today: Sonde Health, which aims to use a voice-based technology to diagnose mental and physical ailments. Based on technology licensed from the Mass. Institute of Technology’s Lincoln Laboratory, Sonde’s device is designed to analyze short vocal samples to screen for conditions based on acoustic changes. “Sonde is developing the technology platform to extract clinically meaningful health information from everyday voice interactions people have on a range of devices they already own,” co-founder & COO Jim Harper said in prepared remarks. “The analysis does not require the content of the speech to be retained, and can readily support the strong security and privacy features users demand with regard to potentially sensitive health information.” “The ability to help recognize early signs of psychiatric illness and monitor treatment responses on devices that people already own is an important step in moving from reactive to preventive care,” added MedStar Georgetown University Hospital’s Aimee Danielson. “This would be particularly useful in conditions that are chronically under-diagnosed, like perinatal mood and anxiety disorders, including postpartum depression, and in other mental health and central nervous system disorders where there is a la...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Diagnostics Wall Street Beat PureTech Sonde Health Source Type: news